Mallinckrodt plc confirmed enrollment of the first patient in the company's Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Read More »
Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial Read More »
The National Institutes of Health is teaming with government, biopharmaceutical, life science and non-profit organizations to overcome obstacles and increase success for advancing promising treatments for Parkinson’s disease (PD). Read More »
Officially approved for leukemia treatment by the FDA just one month ago, Pfizer Inc.’s BESPONSA has gained a primary distributor to provide the drug to pharmacies across the U.S. Read More »
ScriptSave WellRx earned honors at the National Association of Chain Drug Stores (NACDS) Total Store Expo (TSE) this year in San Diego, California, for its Personalized Wellness, designated the front end services product showcase winner. Read More »
A generic formulation of AstraZeneca’s Nexium medication that delivers time-released doses of the drug to aid acid-reflux sufferers has received FDA approval and should soon be available for purchase. Read More »
Taxes are lower, ISIS is on the run, and the regulatory agencies are in a ceasefire with the US economy. Read More »
The Rite Aid Foundation recently announced the rollout of its KidCents Safe Medication Disposal Program, which will focus on reducing drug accessibility, medication misuse and accidental poisoning of children and adolescents. Read More »
The makers of a new, opioid-free inhalable pain reliever have launched a campaign to market the drug to more than 9,000 women’s healthcare providers across the U.S. this fall. Read More »
Novartis recently announced that the U.S. Food and Drug Administration (FDA) approved Kymriah suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Read More »
Merck and researchers from the Clinical Trial Service Unit at the University of Oxford recently announced positive results for the REVEAL Study. Read More »
Coherus BioSciences Inc. of Redwood City, California recently announced initial results from several current clinical pharmacokinetic bioequivalence (PK/BE) studies comparing two products, both developed for the purpose of addressing certain chronic arthritic and skin conditions. Read More »
Endo International plc of Dublin, Ireland recently launched shipping operations for its generic Sabril (vigabatrin for oral solution USP, 500 mg) product via Par Pharmaceutical, following final approval of its Abbreviated New Drug Application (ANDA). Read More »
Orfadin, a drug used to treat a condition causing kidney and liver damage, has now received the FDA’s go-ahead for once-a-day use, cutting its dosing frequency in half. Read More »
Accorda Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) provided a Refusal to File (RTF) letter regarding the company’s New Drug Application (NDA) for Inbrija, an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Read More »
Novo Nordisk recently announced that the U.S. Food and Drug Administration approved a new indication for Victoza, which should help reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV disease. Read More »
Abbott recently announced the initiation of a pivotal clinical study based in the United States that will assess the safety and efficacy of a modified version of its Amplatzer device. Read More »
With the goal of treating dyskinesia in certain Parkinson’s disease patients, Adamas Pharmaceuticals of Emeryville, California recently obtained U.S. Food and Drug Administration approval for its Gocovri (amantadine) extended release capsules. Read More »
Express Scripts, a company that provides pharmacy benefit management services, recently announced research showing significant benefits of adherence to diabetes medications. Read More »
BioMarin Pharmaceuticals' Biologics License Application (BLA) for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme product, has been accepted for Priority Review by the U.S. Food and Drug Administration. Read More »
Alerts Sign-up
